<DOC>
	<DOCNO>NCT00851630</DOCNO>
	<brief_summary>The purpose study twofold : ( 1 ) ass feasibility safety fix dose combination zidovudine/lamivudine/abacavir HIV infect subject tuberculosis resource-limited setting , ( 2 ) ass impact delay versus early initiation strategy fix dose combination zidovudine/lamivudine/abacavir rate tuberculosis-associated immune reconstitution inflammatory syndrome .</brief_summary>
	<brief_title>Tuberculosis Human Immunodeficiency Virus ( HIV ) Immune Reconstitution Syndrome Trial ( THIRST )</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immune Reconstitution Inflammatory Syndrome</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>HIV Infection document rapid HIV test license enzymelinked immunosorbent assay ( ELISA ) test kit confirm different sample . Men woman admit Kibongoto Marangu Hospitals ( ) recent ( within 56 day ) smear positive tuberculosis ( pulmonary extrapulmonary , ) ( b ) total lymphocyte count &lt; 1,200/mm3 , ( c ) less 14 day antituberculous therapy . Antiretroviral naive exception regimen use prevent mothertoinfant transmission HIV pregnancy . The following laboratory value obtain within 45 day prior study entry : absolute neutrophil count ( ANC ) &gt; =700/mmÂ³ , hemoglobin &gt; 8 g/dL woman ; &gt; 9 g/dL men , serum creatinine &lt; = 1.5 time upper limit normal , AST &lt; 5 time upper limit normal . For woman reproductive potential ( reach menopause undergone hysterectomy , bilateral oophorectomy , tubal ligation ) , negative urine pregnancy test within 48 hour study . All subject must agree participate conception process ( e.g. , active attempt become pregnant impregnate ) participate sexual activity could lead pregnancy , female subject/male partner must use condom ( male female ) without spermicidal agent . Not intend relocate area duration study participation . Willingness subject adhere follow schedule . Men woman &gt; = age 13 . Ability willingness subject legal guardian/representative give write consent . Serious illness , tuberculosis , require systematic treatment and/or hospitalization , either completion therapy clinical stability therapy opinion investigator least 14 day prior study entry . Oral vaginal candidiasis , mucocutaneous herpes simple , illness minor opinion site investigator exception Diagnosis suspicion tuberculosis central nervous system . &gt; 14 day antituberculous therapy prior screen . &gt; 28 day antituberculous therapy active tuberculosis within 6 month prior screen . Recent past ( within 28 day study entry ) plan use corticosteroid . Any condition opinion investigator would compromise subject 's ability participate study . Radiation systemic chemotherapy within 45 day entry . Any immunomodulator , HIV vaccine , investigational therapy within 30 day prior study entry . Active drug alcohol use dependence , opinion investigator , would interfere adherence study requirement . Allergy/sensitivity study drug formulation .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>HIV</keyword>
	<keyword>Tuberculosis</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>